Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

MITF controls the TCA cycle to modulate the melanoma hypoxia response.

Louphrasitthiphol P, Ledaki I, Chauhan J, Falletta P, Siddaway R, Buffa FM, Mole DR, Soga T, Goding CR.

Pigment Cell Melanoma Res. 2019 Jun 17. doi: 10.1111/pcmr.12802. [Epub ahead of print]

PMID:
31207090
2.

MITF-the first 25 years.

Goding CR, Arnheiter H.

Genes Dev. 2019 Aug 1;33(15-16):983-1007. doi: 10.1101/gad.324657.119. Epub 2019 May 23. Review.

PMID:
31123060
3.

Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5-/- mice.

Li Y, Tinoco R, Elmén L, Segota I, Xian Y, Fujita Y, Sahu A, Zarecki R, Marie K, Feng Y, Khateb A, Frederick DT, Ashkenazi SK, Kim H, Perez EG, Day CP, Segura Muñoz RS, Schmaltz R, Yooseph S, Tam MA, Zhang T, Avitan-Hersh E, Tzur L, Roizman S, Boyango I, Bar-Sela G, Orian A, Kaufman RJ, Bosenberg M, Goding CR, Baaten B, Levesque MP, Dummer R, Brown K, Merlino G, Ruppin E, Flaherty K, Ramer-Tait A, Long T, Peterson SN, Bradley LM, Ronai ZA.

Nat Commun. 2019 Apr 2;10(1):1492. doi: 10.1038/s41467-019-09525-y.

4.

BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.

Herbert K, Binet R, Lambert JP, Louphrasitthiphol P, Kalkavan H, Sesma-Sanz L, Robles-Espinoza CD, Sarkar S, Suer E, Andrews S, Chauhan J, Roberts ND, Middleton MR, Gingras AC, Masson JY, Larue L, Falletta P, Goding CR.

Genes Dev. 2019 Mar 1;33(5-6):310-332. doi: 10.1101/gad.314633.118. Epub 2019 Feb 25.

5.

Targeting MC1R depalmitoylation to prevent melanomagenesis in redheads.

Chen S, Han C, Miao X, Li X, Yin C, Zou J, Liu M, Li S, Stawski L, Zhu B, Shi Q, Xu ZX, Li C, Goding CR, Zhou J, Cui R.

Nat Commun. 2019 Feb 20;10(1):877. doi: 10.1038/s41467-019-08691-3.

6.

Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.

Yin C, Zhu B, Zhang T, Liu T, Chen S, Liu Y, Li X, Miao X, Li S, Mi X, Zhang J, Li L, Wei G, Xu ZX, Gao X, Huang C, Wei Z, Goding CR, Wang P, Deng X, Cui R.

Cell. 2019 Feb 21;176(5):1113-1127.e16. doi: 10.1016/j.cell.2019.01.002. Epub 2019 Jan 31.

PMID:
30712867
7.

Starvation and Pseudo-Starvation as Drivers of Cancer Metastasis through Translation Reprogramming.

García-Jiménez C, Goding CR.

Cell Metab. 2019 Feb 5;29(2):254-267. doi: 10.1016/j.cmet.2018.11.018. Epub 2018 Dec 20. Review.

PMID:
30581118
8.

BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.

Ngeow KC, Friedrichsen HJ, Li L, Zeng Z, Andrews S, Volpon L, Brunsdon H, Berridge G, Picaud S, Fischer R, Lisle R, Knapp S, Filippakopoulos P, Knowles H, Steingrímsson E, Borden KLB, Patton EE, Goding CR.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8668-E8677. doi: 10.1073/pnas.1810498115. Epub 2018 Aug 27.

9.

A TFEB nuclear export signal integrates amino acid supply and glucose availability.

Li L, Friedrichsen HJ, Andrews S, Picaud S, Volpon L, Ngeow K, Berridge G, Fischer R, Borden KLB, Filippakopoulos P, Goding CR.

Nat Commun. 2018 Jul 11;9(1):2685. doi: 10.1038/s41467-018-04849-7.

10.

Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy.

Zhu B, Tang L, Chen S, Yin C, Peng S, Li X, Liu T, Liu W, Han C, Stawski L, Xu ZX, Zhou G, Chen X, Gao X, Goding CR, Xu N, Cui R, Cao P.

Oncogene. 2018 Sep;37(36):4941-4954. doi: 10.1038/s41388-018-0314-0. Epub 2018 May 22.

PMID:
29786078
11.

Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.

Apps JR, Carreno G, Gonzalez-Meljem JM, Haston S, Guiho R, Cooper JE, Manshaei S, Jani N, Hölsken A, Pettorini B, Beynon RJ, Simpson DM, Fraser HC, Hong Y, Hallang S, Stone TJ, Virasami A, Donson AM, Jones D, Aquilina K, Spoudeas H, Joshi AR, Grundy R, Storer LCD, Korbonits M, Hilton DA, Tossell K, Thavaraj S, Ungless MA, Gil J, Buslei R, Hankinson T, Hargrave D, Goding C, Andoniadou CL, Brogan P, Jacques TS, Williams HJ, Martinez-Barbera JP.

Acta Neuropathol. 2018 May;135(5):757-777. doi: 10.1007/s00401-018-1830-2. Epub 2018 Mar 14.

12.

The protective role of DOT1L in UV-induced melanomagenesis.

Zhu B, Chen S, Wang H, Yin C, Han C, Peng C, Liu Z, Wan L, Zhang X, Zhang J, Lian CG, Ma P, Xu ZX, Prince S, Wang T, Gao X, Shi Y, Liu D, Liu M, Wei W, Wei Z, Pan J, Wang Y, Xuan Z, Hess J, Hayward NK, Goding CR, Chen X, Zhou J, Cui R.

Nat Commun. 2018 Jan 17;9(1):259. doi: 10.1038/s41467-017-02687-7.

13.

Cell and molecular biology: a new section joins the fight against cancer.

Goding CR.

Br J Cancer. 2018 Jan;118(1):1-2. doi: 10.1038/bjc.2017.443. Epub 2017 Dec 12. No abstract available.

14.

Macrophage Cytoplasmic Transfer in Melanoma Invasion.

Louphrasitthiphol P, Goding CR.

Dev Cell. 2017 Dec 4;43(5):543-544. doi: 10.1016/j.devcel.2017.11.012. Review.

15.

Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma.

Gonzalez-Meljem JM, Haston S, Carreno G, Apps JR, Pozzi S, Stache C, Kaushal G, Virasami A, Panousopoulos L, Mousavy-Gharavy SN, Guerrero A, Rashid M, Jani N, Goding CR, Jacques TS, Adams DJ, Gil J, Andoniadou CL, Martinez-Barbera JP.

Nat Commun. 2017 Nov 28;8(1):1819. doi: 10.1038/s41467-017-01992-5.

16.

Palmitoylation-dependent activation of MC1R prevents melanomagenesis.

Chen S, Zhu B, Yin C, Liu W, Han C, Chen B, Liu T, Li X, Chen X, Li C, Hu L, Zhou J, Xu ZX, Gao X, Wu X, Goding CR, Cui R.

Nature. 2017 Sep 21;549(7672):399-403. doi: 10.1038/nature23887. Epub 2017 Sep 6.

17.

KITD816V Induces SRC-Mediated Tyrosine Phosphorylation of MITF and Altered Transcription Program in Melanoma.

Phung B, Kazi JU, Lundby A, Bergsteinsdottir K, Sun J, Goding CR, Jönsson G, Olsen JV, Steingrímsson E, Rönnstrand L.

Mol Cancer Res. 2017 Sep;15(9):1265-1274. doi: 10.1158/1541-7786.MCR-17-0149. Epub 2017 Jun 5.

18.

NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.

Fane ME, Chhabra Y, Hollingsworth DEJ, Simmons JL, Spoerri L, Oh TG, Chauhan J, Chin T, Harris L, Harvey TJ, Muscat GEO, Goding CR, Sturm RA, Haass NK, Boyle GM, Piper M, Smith AG.

EBioMedicine. 2017 Feb;16:63-75. doi: 10.1016/j.ebiom.2017.01.013. Epub 2017 Jan 16.

19.

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.

Falletta P, Sanchez-Del-Campo L, Chauhan J, Effern M, Kenyon A, Kershaw CJ, Siddaway R, Lisle R, Freter R, Daniels MJ, Lu X, Tüting T, Middleton M, Buffa FM, Willis AE, Pavitt G, Ronai ZA, Sauka-Spengler T, Hölzel M, Goding CR.

Genes Dev. 2017 Jan 1;31(1):18-33. doi: 10.1101/gad.290940.116. Epub 2017 Jan 17.

20.

Multivalent Histone and DNA Engagement by a PHD/BRD/PWWP Triple Reader Cassette Recruits ZMYND8 to K14ac-Rich Chromatin.

Savitsky P, Krojer T, Fujisawa T, Lambert JP, Picaud S, Wang CY, Shanle EK, Krajewski K, Friedrichsen H, Kanapin A, Goding C, Schapira M, Samsonova A, Strahl BD, Gingras AC, Filippakopoulos P.

Cell Rep. 2016 Dec 6;17(10):2724-2737. doi: 10.1016/j.celrep.2016.11.014.

21.

Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers.

Pérez-Guijarro E, Karras P, Cifdaloz M, Martínez-Herranz R, Cañón E, Graña O, Horcajada-Reales C, Alonso-Curbelo D, Calvo TG, Gómez-López G, Bellora N, Riveiro-Falkenbach E, Ortiz-Romero PL, Rodríguez-Peralto JL, Maestre L, Roncador G, de Agustín Asensio JC, Goding CR, Eyras E, Megías D, Méndez R, Soengas MS.

Nat Commun. 2016 Nov 18;7:13418. doi: 10.1038/ncomms13418.

22.

Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP.

Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, Ratnayaka I, Sullivan A, Brown NR, Endicott J, Knapp S, Kessler BM, Middleton MR, Siebold C, Jones EY, Sviderskaya EV, Cebon J, John T, Caballero OL, Goding CR, Lu X.

Cancer Cell. 2016 Nov 14;30(5):822-823. doi: 10.1016/j.ccell.2016.09.019. No abstract available.

23.

Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.

Faião-Flores F, Alves-Fernandes DK, Pennacchi PC, Sandri S, Vicente AL, Scapulatempo-Neto C, Vazquez VL, Reis RM, Chauhan J, Goding CR, Smalley KS, Maria-Engler SS.

Oncogene. 2017 Mar 30;36(13):1849-1861. doi: 10.1038/onc.2016.348. Epub 2016 Oct 17.

24.

Targeting the lncRNA SAMMSON Reveals Metabolic Vulnerability in Melanoma.

Goding CR.

Cancer Cell. 2016 May 9;29(5):619-621. doi: 10.1016/j.ccell.2016.04.010.

25.

The importance of p53 pathway genetics in inherited and somatic cancer genomes.

Stracquadanio G, Wang X, Wallace MD, Grawenda AM, Zhang P, Hewitt J, Zeron-Medina J, Castro-Giner F, Tomlinson IP, Goding CR, Cygan KJ, Fairbrother WG, Thomas LF, Sætrom P, Gemignani F, Landi S, Schuster-Böckler B, Bell DA, Bond GL.

Nat Rev Cancer. 2016 Apr;16(4):251-65. doi: 10.1038/nrc.2016.15. Review.

PMID:
27009395
26.

Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion.

Vlahov N, Scrace S, Soto MS, Grawenda AM, Bradley L, Pankova D, Papaspyropoulos A, Yee KS, Buffa F, Goding CR, Timpson P, Sibson N, O'Neill E.

Curr Biol. 2015 Dec 7;25(23):3019-34. doi: 10.1016/j.cub.2015.09.072. Epub 2015 Nov 5.

27.

MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.

Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J, Smorra D, Kohlmeyer J, Renn M, Phung B, Aymans P, Schmidt T, Hornung V, Davidson I, Goding CR, Jönsson G, Landsberg J, Tüting T, Hölzel M.

Nat Commun. 2015 Nov 4;6:8755. doi: 10.1038/ncomms9755.

28.

The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth.

Cao J, Dai X, Wan L, Wang H, Zhang J, Goff PS, Sviderskaya EV, Xuan Z, Xu Z, Xu X, Hinds P, Flaherty KT, Faller DV, Goding CR, Wang Y, Wei W, Cui R.

Sci Signal. 2015 Sep 1;8(392):ra87. doi: 10.1126/scisignal.aab1995.

PMID:
26329581
29.

MITF is a critical regulator of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in malignant melanoma.

Ullrich N, Löffek S, Horn S, Ennen M, Sánchez-Del-Campo L, Zhao F, Breitenbuecher F, Davidson I, Singer BB, Schadendorf D, Goding CR, Helfrich I.

Pigment Cell Melanoma Res. 2015 Nov;28(6):736-40. doi: 10.1111/pcmr.12414.

PMID:
26301891
30.

Afamelanotide for Erythropoietic Protoporphyria.

Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FPJ, Sijbrands EJG, de Rooij FWM, Lebwohl M, Naik H, Goding CR, Wilson JHP, Desnick RJ.

N Engl J Med. 2015 Jul 2;373(1):48-59. doi: 10.1056/NEJMoa1411481.

31.

Mitf is a master regulator of the v-ATPase, forming a control module for cellular homeostasis with v-ATPase and TORC1.

Zhang T, Zhou Q, Ogmundsdottir MH, Möller K, Siddaway R, Larue L, Hsing M, Kong SW, Goding CR, Palsson A, Steingrimsson E, Pignoni F.

J Cell Sci. 2015 Aug 1;128(15):2938-50. doi: 10.1242/jcs.173807. Epub 2015 Jun 19.

32.

Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancer.

Grawenda AM, Møller EK, Lam S, Repapi E, Teunisse AF, Alnæs GI, Børresen-Dale AL, Kristensen VN, Goding CR, Jochemsen AG, Edvardsen H, Bond GL.

Cancer Res. 2015 Feb 15;75(4):698-708. doi: 10.1158/0008-5472.CAN-14-2637. Epub 2015 Feb 3.

33.

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS.

Nat Commun. 2014 Dec 15;5:5712. doi: 10.1038/ncomms6712.

34.

The anti-proliferative function of the TGF-β1 signaling pathway involves the repression of the oncogenic TBX2 by its homologue TBX3.

Li J, Ballim D, Rodriguez M, Cui R, Goding CR, Teng H, Prince S.

J Biol Chem. 2014 Dec 19;289(51):35633-43. doi: 10.1074/jbc.M114.596411. Epub 2014 Nov 4.

35.

Sensitivity to anti-BRAF therapy: lost in translation.

Kalkavan H, Goding CR.

Pigment Cell Melanoma Res. 2015 Jan;28(1):4-5. doi: 10.1111/pcmr.12314. Epub 2014 Sep 30. No abstract available.

PMID:
25220342
36.

T-box transcription factors in cancer biology.

Wansleben S, Peres J, Hare S, Goding CR, Prince S.

Biochim Biophys Acta. 2014 Dec;1846(2):380-91. doi: 10.1016/j.bbcan.2014.08.004. Epub 2014 Aug 19. Review.

PMID:
25149433
37.

Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma.

Jayachandran A, Anaka M, Prithviraj P, Hudson C, McKeown SJ, Lo PH, Vella LJ, Goding CR, Cebon J, Behren A.

Oncotarget. 2014 Jul 30;5(14):5782-97.

38.

Cancer: pathological nuclear reprogramming?

Goding CR, Pei D, Lu X.

Nat Rev Cancer. 2014 Aug;14(8):568-73. doi: 10.1038/nrc3781. Epub 2014 Jul 17. Review.

PMID:
25030952
39.

Chromatin barcodes as biomarkers for melanoma.

Bastonini E, Jeznach M, Field M, Juszczyk K, Corfield E, Dezfouli M, Ahmat N, Smith A, Womersley H, Jordan P, Ramadass A, Akoulitchev A, Goding CR.

Pigment Cell Melanoma Res. 2014 Sep;27(5):788-800. doi: 10.1111/pcmr.12258. Epub 2014 May 27.

PMID:
24807349
40.

Melanosome-autonomous regulation of size and number: the OA1 receptor sustains PMEL expression.

Falletta P, Bagnato P, Bono M, Monticone M, Schiaffino MV, Bennett DC, Goding CR, Tacchetti C, Valetti C.

Pigment Cell Melanoma Res. 2014 Jul;27(4):565-79. doi: 10.1111/pcmr.12239. Epub 2014 Apr 11.

PMID:
24650003
41.

Three BRNs are better than two.

Goding CR.

Pigment Cell Melanoma Res. 2013 Nov;26(6):789-90. doi: 10.1111/pcmr.12150. Epub 2013 Aug 14. No abstract available.

PMID:
24152042
42.

Fishful thinking: the rise and fall of MITF in melanoma.

Goding CR.

Pigment Cell Melanoma Res. 2014 Jan;27(1):7-8. doi: 10.1111/pcmr.12177. Epub 2013 Oct 23. No abstract available.

PMID:
24118901
43.

MC1R is a potent regulator of PTEN after UV exposure in melanocytes.

Cao J, Wan L, Hacker E, Dai X, Lenna S, Jimenez-Cervantes C, Wang Y, Leslie NR, Xu GX, Widlund HR, Ryu B, Alani RM, Dutton-Regester K, Goding CR, Hayward NK, Wei W, Cui R.

Mol Cell. 2013 Aug 22;51(4):409-22. doi: 10.1016/j.molcel.2013.08.010.

44.

Analysis of Dll4 regulation reveals a combinatorial role for Sox and Notch in arterial development.

Sacilotto N, Monteiro R, Fritzsche M, Becker PW, Sanchez-Del-Campo L, Liu K, Pinheiro P, Ratnayaka I, Davies B, Goding CR, Patient R, Bou-Gharios G, De Val S.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11893-8. doi: 10.1073/pnas.1300805110. Epub 2013 Jul 1.

45.

Directed phenotype switching as an effective antimelanoma strategy.

Sáez-Ayala M, Montenegro MF, Sánchez-Del-Campo L, Fernández-Pérez MP, Chazarra S, Freter R, Middleton M, Piñero-Madrona A, Cabezas-Herrera J, Goding CR, Rodríguez-López JN.

Cancer Cell. 2013 Jul 8;24(1):105-19. doi: 10.1016/j.ccr.2013.05.009. Epub 2013 Jun 20.

46.

Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP.

Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, Ratnayaka I, Sullivan A, Brown NR, Endicott J, Knapp S, Kessler BM, Middleton MR, Siebold C, Jones EY, Sviderskaya EV, Cebon J, John T, Caballero OL, Goding CR, Lu X.

Cancer Cell. 2013 May 13;23(5):618-33. doi: 10.1016/j.ccr.2013.03.013. Epub 2013 Apr 25. Erratum in: Cancer Cell. 2016 Nov 14;30(5):822-823.

47.

The path of least resistance: enhancing the effectiveness of BRAF inhibitors.

Goding CR.

Pigment Cell Melanoma Res. 2013 Mar 7. doi: 10.1111/pcmr.12087. [Epub ahead of print] No abstract available.

PMID:
23531035
48.

Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion.

Boyd SC, Mijatov B, Pupo GM, Tran SL, Gowrishankar K, Shaw HM, Goding CR, Scolyer RA, Mann GJ, Kefford RF, Rizos H, Becker TM.

J Invest Dermatol. 2013 May;133(5):1269-77. doi: 10.1038/jid.2012.421. Epub 2012 Nov 29.

49.

TBX2 expression is regulated by PAX3 in the melanocyte lineage.

Liu F, Cao J, Lv J, Dong L, Pier E, Xu GX, Wang RA, Xu Z, Goding C, Cui R.

Pigment Cell Melanoma Res. 2013 Jan;26(1):67-77. doi: 10.1111/pcmr.12029. Epub 2012 Nov 21.

50.

A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma.

Bonvin E, Falletta P, Shaw H, Delmas V, Goding CR.

Mol Cell Biol. 2012 Nov;32(22):4674-83. doi: 10.1128/MCB.01067-12. Epub 2012 Sep 17.

Supplemental Content

Loading ...
Support Center